Maria Rosa Costanzo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Rosa Costanzo has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Christoph Stellbrink
Bielefeld Medical Center, Bielefeld, Germany
5 shared publicationsRalph Augostini
The Ohio State University, Columbus, OH, USA
5 shared publicationsWilliam T. Abraham
The Ohio State University, Columbus, OH, USA
5 shared publications- Gregg Fonarow
Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
4 shared publications - Piotr Ponikowski
Wroclaw Medical University
4 shared publications Shahrokh Javaheri
Bethesda North Hospital, Cincinnati, OH, USA
4 shared publications
Latest Publications
- 21 April 2022
- Published by Elsevier in Cardiology Clinics
- Vol. 40 (2) , 219-235
The Cardiorenal Syndrome in Heart Failure
- 21 April 2022
- Published by Elsevier in Cardiology Clinics
- Vol. 40 (2) , 219-235
The Cardiorenal Syndrome in Heart Failure
- 25 November 2020
- Published by Springer Nature
- p. 177-206
Methods to Assess Intra- and Extravascular Volume Status in Heart Failure Patients
- 25 November 2020
- Published by Springer Nature
- p. 177-206
Methods to Assess Intra- and Extravascular Volume Status in Heart Failure Patients
- 17 August 2020
- Published by Springer Nature in Current Heart Failure Reports
- Vol. 17 (5) , 277-287
Central Sleep Apnea in Patients with Heart Failure—How to Screen, How to Treat
Purpose of Review Central sleep apnea occurs in up to 50% of heart failure patients and worsens outcomes. Established therapies are limited by minimal supporting evidence, poor patient adherence, and potentially adverse cardiovascular effects. However, transvenous phrenic nerve stimulation, by contracting the diaphragm, restores normal breathing throughout sleep and has been shown to be safe and effective. This review discusses the mechanisms, screening, diagnosis, and therapeutic approaches to CSA in patients with HF. Recent Findings In a prospective, multicenter randomized Pivotal Trial (NCT01816776) of transvenous phrenic nerve stimulation with the remedē System, significantly more treated patients had a ≥ 50% reduction in apnea-hypopnea index compared with controls, with a 41 percentage point difference between group difference at 6 months (p < 0.0001). All hierarchically tested sleep, quality of life, and daytime sleepiness endpoints were significantly improved in treated patients. Freedom from serious related adverse events at 12 months was 91%. Benefits are sustained to 36 months. Summary Transvenous phrenic nerve stimulation improves quality of life in patients with heart failure and central sleep apnea. Controlled trials evaluating the impact of this therapy on mortality/heart failure hospitalizations and “real world” experience are needed to confirm safety and effectiveness.
- 17 August 2020
- Published by Springer Nature in Current Heart Failure Reports
- Vol. 17 (5) , 277-287
Central Sleep Apnea in Patients with Heart Failure—How to Screen, How to Treat
Purpose of Review Central sleep apnea occurs in up to 50% of heart failure patients and worsens outcomes. Established therapies are limited by minimal supporting evidence, poor patient adherence, and potentially adverse cardiovascular effects. However, transvenous phrenic nerve stimulation, by contracting the diaphragm, restores normal breathing throughout sleep and has been shown to be safe and effective. This review discusses the mechanisms, screening, diagnosis, and therapeutic approaches to CSA in patients with HF. Recent Findings In a prospective, multicenter randomized Pivotal Trial (NCT01816776) of transvenous phrenic nerve stimulation with the remedē System, significantly more treated patients had a ≥ 50% reduction in apnea-hypopnea index compared with controls, with a 41 percentage point difference between group difference at 6 months (p < 0.0001). All hierarchically tested sleep, quality of life, and daytime sleepiness endpoints were significantly improved in treated patients. Freedom from serious related adverse events at 12 months was 91%. Benefits are sustained to 36 months. Summary Transvenous phrenic nerve stimulation improves quality of life in patients with heart failure and central sleep apnea. Controlled trials evaluating the impact of this therapy on mortality/heart failure hospitalizations and “real world” experience are needed to confirm safety and effectiveness.
- 1 January 2020
- Published by Elsevier in Heart Failure Clinics
- Vol. 16 (1) , 81-97
The Cardiorenal Syndrome in Heart Failure
- 1 January 2020
- Published by Elsevier in Heart Failure Clinics
- Vol. 16 (1) , 81-97
The Cardiorenal Syndrome in Heart Failure
- Open Access
- 11 February 2019
- Published by Radcliffe Medical Media Ltd in Cardiac Failure Review
- Vol. 5 (1) , 9-18
Ultrafiltration in Acute Heart Failure
Congestion is the predominant cause of more than 1 million annual heart failure hospitalisations and recurrent fluid overload predicts poor outcomes. Unresolved congestion trumps serum creatinine increases in predicting adverse heart failure outcomes. No pharmacological approach for acute heart failure has reduced these deleterious consequences. Simplified ultrafiltration devices permit fluid removal in lower acuity hospital settings, but results regarding safety and efficacy have been variable. However, adjustment of ultrafiltration rates to patients’ vital signs and renal function has been associated with more effective decongestion and fewer heart failure events. Many aspects of ultrafiltration, including patient selection, fluid removal rates, venous access, prevention of therapy- related complications and costs, require further investigation.
- 11 February 2019
- Published by Radcliffe Medical Media Ltd in Cardiac Failure Review
- Vol. 5 (1) , 9-18
Open AccessUltrafiltration in Acute Heart Failure
Congestion is the predominant cause of more than 1 million annual heart failure hospitalisations and recurrent fluid overload predicts poor outcomes. Unresolved congestion trumps serum creatinine increases in predicting adverse heart failure outcomes. No pharmacological approach for acute heart failure has reduced these deleterious consequences. Simplified ultrafiltration devices permit fluid removal in lower acuity hospital settings, but results regarding safety and efficacy have been variable. However, adjustment of ultrafiltration rates to patients’ vital signs and renal function has been associated with more effective decongestion and fewer heart failure events. Many aspects of ultrafiltration, including patient selection, fluid removal rates, venous access, prevention of therapy- related complications and costs, require further investigation.
- Open Access
- 10 October 2018
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 20 (12) , 1746-1754
Phrenic Nerve Stimulation to Treat Patients with Central Sleep Apnoea and Heart Failure
Aims The presence of central sleep apnoea (CSA) is associated with poor prognosis in patients with heart failure (HF). The aim of this analysis was to evaluate if using phrenic nerve stimulation to treat CSA in patients with CSA and HF was associated with changes in HF‐specific metrics. Methods and results All patients randomized in the remedē System Pivotal Trial and identified at baseline with HF were included (n = 96). Effectiveness data from treatment and former control groups were pooled based on months since therapy activation. Changes from baseline to 6 and 12 months in sleep metrics, Epworth Sleepiness Scale, patient global assessment health‐related quality of life, Minnesota Living with Heart Failure Questionnaire (MLHFQ), and echocardiographic parameters are reported. HF hospitalization, cardiovascular death, and the composite of HF hospitalization or cardiovascular death within 6 months are reported by the original randomized group assignment for safety assessment. Sleep metrics and quality of life improved from baseline to 6 and 12 months. At 12 months, MLHFQ scores changed by –6.8 ± 20.0 (P = 0.005). The 6‐month rate of HF hospitalization was 4.7% in treatment patients (standard error = 3.3) and 17.0% in control patients (standard error = 5.5) (P = 0.065). Reported adverse events were as expected for a transvenous implantable system. Conclusions Phrenic nerve stimulation reduces CSA severity in patients with HF. In parallel, this CSA treatment was associated with benefits on HF quality of life.
- 10 October 2018
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 20 (12) , 1746-1754
Open AccessPhrenic Nerve Stimulation to Treat Patients with Central Sleep Apnoea and Heart Failure
Aims The presence of central sleep apnoea (CSA) is associated with poor prognosis in patients with heart failure (HF). The aim of this analysis was to evaluate if using phrenic nerve stimulation to treat CSA in patients with CSA and HF was associated with changes in HF‐specific metrics. Methods and results All patients randomized in the remedē System Pivotal Trial and identified at baseline with HF were included (n = 96). Effectiveness data from treatment and former control groups were pooled based on months since therapy activation. Changes from baseline to 6 and 12 months in sleep metrics, Epworth Sleepiness Scale, patient global assessment health‐related quality of life, Minnesota Living with Heart Failure Questionnaire (MLHFQ), and echocardiographic parameters are reported. HF hospitalization, cardiovascular death, and the composite of HF hospitalization or cardiovascular death within 6 months are reported by the original randomized group assignment for safety assessment. Sleep metrics and quality of life improved from baseline to 6 and 12 months. At 12 months, MLHFQ scores changed by –6.8 ± 20.0 (P = 0.005). The 6‐month rate of HF hospitalization was 4.7% in treatment patients (standard error = 3.3) and 17.0% in control patients (standard error = 5.5) (P = 0.065). Reported adverse events were as expected for a transvenous implantable system. Conclusions Phrenic nerve stimulation reduces CSA severity in patients with HF. In parallel, this CSA treatment was associated with benefits on HF quality of life.
- 1 September 2018
- Published by Elsevier in Advances in Chronic Kidney Disease
- Vol. 25 (5) , 434-442
Extracorporeal Isolated Ultrafiltration for Management of Congestion in Heart Failure and Cardiorenal Syndrome
- 1 September 2018
- Published by Elsevier in Advances in Chronic Kidney Disease
- Vol. 25 (5) , 434-442
Extracorporeal Isolated Ultrafiltration for Management of Congestion in Heart Failure and Cardiorenal Syndrome
- 1 July 2018
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 11 (7) , e004894
The Luck of Having a Cardiac Implantable Electronic Device
- 1 July 2018
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 11 (7) , e004894
The Luck of Having a Cardiac Implantable Electronic Device
- Open Access
- 1 June 2018
- Published by Elsevier in The American Journal of Cardiology
- Vol. 121 (11) , 1400-1408
Sustained 12 Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea
- 1 June 2018
- Published by Elsevier in The American Journal of Cardiology
- Vol. 121 (11) , 1400-1408
Open AccessSustained 12 Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea